A Randomized, Control,Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker.

Trial Profile

A Randomized, Control,Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Cilostazol (Primary) ; Probucol (Primary)
  • Indications Arteriosclerosis obliterans; Embolism and thrombosis
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 16 Jan 2010 Planned end date changed from 1 Jul 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov
    • 27 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov
    • 22 Jan 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top